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Abstract
Purpose The incidence of neuroendocrine neoplasms is
increasing. This work aimed at: (i) establishing worldwide
incidence trend of low-grade neuroendocrine neoplasms;
(ii) deﬁning the incidence and temporal trend of high-grade
neuroendocrine neoplasms in USA utilizing the Surveil-
lance Epidemiology and End Results database; (iii) com-
paring trends for low-grade vs. high-grade neuroendocrine
neoplasms.
Methods We conducted a literature search on MEDLINE
and Scopus databases and incidence trends were plotted for
1973-2012. The Surveillance Epidemiology and End
Results database was used to identify incidence rates in
USA for 1973-2012. Incidence rates were stratiﬁed
according to histological grade, gender and ethnicity.
Trends were summarized as annual percent change and
corresponding 95% conﬁdence interval.
Results 11 studies were identiﬁed involving 72,048 cases;
neuroendocrine neoplasm incidence rates increased over
time in all countries for all sites, except for appendix. In
Surveillance Epidemiology and End Results low-grade
neuroendocrine neoplasm incidence rate increased from
1.09 in 1973 to 3.51 per 100,000 in 2012. During this
interval, high-grade neuroendocrine neoplasm incidence
rate increased from 2.54 to 10.52 per 100,000. African
Americans had the highest rates of digestive neuroendocrine
neoplasms with male prevalence in high-grade.
Conclusions Our data indicate an increase in the incidence
of neuroendocrine neoplasms as a worldwide phenomenon,
affecting most anatomical sites and involving both low-
grade and high-grade neoplasms.
Keywords Neuroendocrine ● Cancer ● Low-grade ● High-
grade ● Incidence
Introduction
Neuroendocrine deﬁne those neoplasms exclusively made
by cells with a neuroendocrine phenotype, i.e., expressing
markers of neuroendocrine differentiation like chromo-
granin A, synaptophysin, neuron speciﬁc enolase and others
including hormones. As such, neuroendocrine neoplasms
(NENs) may develop at any anatomical site [1]. The present
paper focuses on NENs of the gastroenteropancreatic (GEP)
tract. The current World Health Organization (WHO)
classiﬁcation of GEP NENs deﬁnes neuroendocrine tumor
(NET) as well differentiated low to intermediate grade, and
neuroendocrine carcinomas (NEC) as high grade neo-
plasms, poorly differentiated in phenotype [2]. Recent
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evidences also identiﬁed well differentiated NENs of high
grade (for review and deﬁnition see [3]), now endorsed by
the American Joint Cancer Committee Cancer Staging
Manual [4, 5] and heralding a yet-to-come WHO classiﬁ-
cation change.
Global incidence of GEP NENs appears to be increasing.
In the last four decades, incremental trends were reported in
various populations for NENs overall and for speciﬁc pri-
mary sites [6–16]. Data were obtained from different
population-based registries, which varied in completeness
and time periods. Seminal papers were generated from the
Surveillance, Epidemiology, and End Results (SEER) pro-
gram of the US collecting cancer information since 1973,
probably one of the most complete cancer registry publicly
available in western countries [9, 17].
Published investigations focused broadly on NENs and
were generated utilizing general “neuroendocrine” ICD-O
codes potentially mixing cancers with different biology.
Available data are thus difﬁcult to interpret, and are com-
monly intended as referring to NENs of low to intermediate
grade (from now on low-grade NENs), either deﬁned as
carcinoids, atypical carcinoids or, more recently, neu-
roendocrine tumors (NETs). Limited epidemiological data
is available for poorly differentiated, high-grade NENs
(from now on high-grade NENs) [18, 19].
Aims of this work were: (i) establishing worldwide
trends in the incidence of low-grade NENs; (ii) deﬁning the
incidence and temporal trend of high-grade NENs in USA
utilizing the Surveillance Epidemiology and End Results
(SEER) database; (iii) comparing trends for low- vs. high-
grade NENs.
Materials and methods
Published studies data analysis
Search strategy
We conducted a systematic review according to PRISMA
guidelines [20] aiming at identifying studies on NEN inci-
dence. We searched MEDLINE and Scopus with the fol-
lowing keywords: “neuroendocrine”, “carcinoid”,
“epidemiology”, “trend” and “incidence”. The search was
limited to English studies on human subjects till October 1,
2015. References of included articles were screened for any
additional eligible study.
Inclusion and exclusion criteria
Inclusion criteria required that the study: (i) reported inci-
dence estimates for NENs overall or for site-speciﬁc NENs;
(ii) reported incidence estimates for at least 10-years with at
least two time points; (iii) used data series from population-
based surveillance systems. If articles reported data on
overlapping regions or time intervals, the study with the
most recent information was included. Studies reporting
NEN incidence estimates in USA were excluded as we
generated results for this country based on the most recent
data available from the SEER database.
Data extraction
Titles and abstracts of articles obtained from the literature
search were reviewed for eligibility by two authors (EL and
KA). Papers successfully meeting the inclusion criteria were
selected for data extraction. The investigators independently
extracted the following information: ﬁrst author’s name,
publication year, study location, study period, cancer site
(including topographical and morphological codes), number
of cases, incidence rates, and standard population used for
adjustment. We extracted data according to sex or racial/
ethnic group, whenever available.
Summarization of data
International trends in incidence were plotted for all NENs
combined and for most common primary sites for the period
1973–2012. Measures of incidence presented are those
reported in the individual studies. Any measure also
depends on the standard population used for the adjustment.
When studies reported incidence rates separately for men
and women, an average incidence rate was computed.
NEN incidence in the United States
We used the SEER database to identify NEN incidence
rates in the United States [21]. The SEER program, started
in 1973, currently registers cancer incidence and subsequent
cause-speciﬁc mortality in 30% US population.
In order to provide comparable data with published
incidence data, but also to be as much as possible consistent
with the current classiﬁcation systems for pure NENs,
records were selected based on the following ICD-O-3
(International Classiﬁcation of Diseases for Oncology)
morphological codes: M8150/3 (Islet cell carcinoma),
M8151/3 (insulinoma), M8152/3 (glucagonoma), M8153/3
(gastrinoma), M8155/3 (vipoma), M8156/3 (somatostati-
noma), M8240/3 (carcinoid tumor, not appendix), M8241/3
(carcinoid tumor, argentafﬁn), M8242/3 (enter-
ochromafﬁnlike-cell tumor), M8246/3 (neuroendocrine
carcinoma), M8249/3 (atypical carcinoid).
Low-grade NENs were selected based on the following
ICD-O-3 codes: M8150/3, M8151/3, M8152/3, M8153/3,
M8155/3, M8156/3, M8240/3, M8241/3, M8242/3, M8249/
3; whereas high-grade NENs were selected based on the
Endocrine
following codes: M8013/3 (large cell neuroendocrine car-
cinoma), M8041/3 (small cell carcinoma), M8246/3 (neu-
roendocrine carcinoma). Codes identifying cancer types of
mixed neuroendocrine/non-neuroendocrine phenotype (e.g.,
goblet cell carcinoid, mixed adeno-neuroendocrine carci-
noma) were excluded.
Statistical analysis
Age-adjusted incidence rates of NENs for the most common
primary sites (lung and bronchus, stomach, pancreas, small
intestine, colon, appendix, rectum) and for all sites com-
bined for the 40 years period 1973–2012, were reported.
Incidence data were obtained from the SEER 9 registries for
years 1973–1991, from the SEER 13 registries for years
1992–1999 and from the SEER 18 registries for the years
2000–2012.
Incidence rates according to histological classiﬁcation of
malignancy grade and by gender and by ethnicity (white,
black, Asian Paciﬁc/Islander) for 2000 through 2012 were
collected from the SEER 18 registries were reported to
further assess whether overall changes in incidence rates
were uniform or more marked for speciﬁc groups. All rates
are expressed per 100,000 persons and age-adjusted
according to the 2000 US standard population.
Trends for the period 2000–2012 were summarized with
the annual percent change (APC) (Joinpoint Regression
Program, Version 4.3.1.0 - April 2016; Statistical Metho-
dology and Applications Branch, Surveillance Research
Program, National Cancer Institute) and corresponding 95%
conﬁdence interval (CI) [22]. A sensitivity analysis of
trends according to histological grade restricted to the SEER
9 registries with complete data during the period
1975–2012, was done.
Male-to-female (M:F) ratios, based on the most recently
available incidence data from the 2010–2012 SEER, were
also computed. Stata software (StataCorp. 2013. Stata Sta-
tistical Software: Release 13. College Station, TX: Stata-
Corp LP) was used for data management and to produce
graphs.
Results
Review of worldwide incidence of NEN
The results of the bibliographic search are summarized in
Fig. 1. A total of 4114 articles were considered. After
excluding duplicates, reviews and studies unrelated to the
search topic, we assessed for eligibility of 31 full-text arti-
cles. Of these, 20 articles were excluded after full review.
Table 1 shows the main characteristics of the studies
included and the SEER Program. The 11 studies were
4114
Records identified through 
database searching








10 - year period with at least 2
20 
Full-text articles excluded
6 did not report incidence rates
6 reported incidence rates in 
USA
4 were not population-based
3 did not report incidence rates 
for periods spanning at least a 
time points
1 reported trends in incidence 
for malignant digestive NEN 
combined
2441
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































published between 2000 and 2015 and involved a total of
72,048 cases. Nine were conducted in Europe [6–12, 15],
one in Canada [16], and one in Taiwan [13] (Fig. 2). In ﬁve
countries (Denmark, England, The Netherlands, Norway,
Taiwan), the incidence data covered the entire national
population, while in the other six countries, covered 1% to
30% of the population.
Seven studies reporting details on ICD-O codes included
the ambiguous neuroendocrine carcinoma (M8246/3;
ambiguous since could have comprised both low-grade and
high-grade NENs), six included codes of mixed
neuroendocrine–non neuroendocrine cancer (e.g. M8243
goblet cell carcinoid), and two included the high-grade large
cell neuroendocrine carcinoma (Table 2). Thus, the pub-
lished data were not fully comparable and homogenous for
neuroendocrine cancer types collected, either non-purely
neuroendocrine and/or of different grades.
NEN incidence in the United States
Trends in incidence for NENs overall and for common
primary sites are shown in Fig. 3a and detailed in Table 3.
Incidence data of all NENs combined were available for
seven countries. In USA and EU countries for which trend
data was available, the incidence of NENs increased stea-
dily. The incidence also increased in Taiwan (from 0.30 in
1996 to 1.51 in 2008), where it was relatively low compared
to other countries. In the United States, NEN incidence
increased from 1.52 to 7.41 cases per 100,000 from 1973 to
2012; this represented a 4.88-fold increase.
Incidence rates of all site-speciﬁc NENs increased over
time in all countries for all sites, except for appendix
(supplementary Fig. 1). Rates of appendix NENs have been
increasing over time in England and Norway, while
remained stable in Germany, the Netherlands and the Uni-
ted States.
NEN incidence in the United States by grade
The age-adjusted incidence rates of NENs according to
histological grade from 1973 to 2012 are illustrated in
Fig. 3b–d. The overall incidence rate of low-grade NENs
increased from 1.09 per 100,000 in 1973 to 3.51 in 2012
(Fig. 3b); this represented a 3.2-fold increase. During the
same interval, the overall incidence rate of high-grade
NENs increased from 2.54 per 100,000 to 10.52 (Fig. 3b);
this represented a 4.1-fold increase.
During 2000–2012, the incidence rate of low-grade
NENs (Fig. 3c and supplementary Fig. 2) increased in the
lung (0.63 per 100,000 in 1973 vs 0.75 per 100,000 in
2012; APC: 1.74, 95% CI: 1.21, 2.27), stomach (0.22 per
100,000 in 1973 vs 0.31 per 100,000 in 2012; APC: 3.03,
95% CI: 1.65, 4.43), appendix (0.02 per 100,000 in 1973 vs
0.13 per 100,000 in 2012; APC: 12.07, 95% CI: 6.86,
17.54), and rectum (0.69 per 100,000 in 1973 vs 0.89 per
100,000 in 2012; APC: 2.52, 95% CI: 0.90, 4.17). By
converse, the incidence rate of pancreas and small intestine
tumors remained stable, while for colon it decreased (0.20
per 100,000 in 1973 vs 0.14 per 100,000 in 2012; APC:
−2.65, 95% CI: −5.26, −0.03). In 2012, the highest inci-
dence rate of low-grade NENs was observed for rectum
(0.89 per 100,000), followed by the small intestine (0.83 per
100,000), and lung (0.75 per 100,000). Overall, the inci-
dence of digestive low-grade NENs was 2.54 per 100,000.
During 2000–2012, the incidence rates of high-grade
NENs (Fig. 3d and supplementary Fig. 2), increased over
time for all sites, except for lung, for which a decreasing
trend was observed (8.62 per 100,000 in 1973 vs 7.47 per














































































































































































































































































































































































































































































































































































































































































100,000 in 2012; APC: −1.14, 95% CI: −1.63, −0.64)
(Fig. 3b and supplementary Fig. 2). During the same period,
the small intestine showed the largest APC (0.07 per
100,000 in 1973 vs 0.46 per 100,000 in 2012; APC 20.68,
95% CI: 17.8, 23.7), while the colon showed the lowest
APC (0.14 per 100,000 in 1973 vs 0.20 per 100,000 in
2012; APC 4.09, 95% CI: 2.56, 5.64) (Fig. 3d and sup-
plementary Fig. 2). Lung cancer was the most frequently
diagnosed high-grade NEN (7.47 per 100,000), accounting
for 71% of the total new high-grade NEN cases in 2012.
Overall the incidence of digestive high-grade NENs was
1.72 per 100,000.
Incidence rates of NENs from 2000 to 2012 according to
grade by gender are presented overall and by anatomical
site in Supplementary Figs. 3 and 4. Incidence rates of low-
grade and high-grade NENs demonstrated a similar pattern
in both males and females. When taking into account all the
NEN cases over the last 3 years, the overall M:F ratio was
0.9 and 1.2 for low-grade and high-grade NENs,
respectively.
Incidence rates of NENs from 2000 to 2012 according to
grade for three ethnic populations are presented overall and
by anatomical site in Supplementary Figs. 5 and 6. In the
period 2010–2012, within the low-grade NENs, African
Americans showed the highest overall incidence rate (5.57
per 100,000), followed by whites (3.28 per 100,000), and
Asians/Paciﬁc Islanders (2.21 per 100,000). In the same
period, within the high-grade NENs, whites had the highest
overall incidence rate (11.02 per 100,000), followed by
African Americans (10.56 per 100,000), and Asians/Paciﬁc
Islanders (4.75 per 100,000).
Sensitivity analyses restricted to SEER 9 registries with
complete data (period 1975–2012) revealed incidence
trends for NEN according to histological grade, comparable
to those obtained from different combinations of SEER
registries in terms of both magnitude and statistical sig-
niﬁcance (data not shown).
Discussion
This work aimed at deﬁning the current pattern and trend in
the incidence of NENs worldwide, and at analyzing the
SEER database for more detailed results. Based on the
codes here utilized, only pure neuroendocrine cancers were
investigated. Additionally, of the recently recognized high
grade NEN types (G3 NET and NEC), the present investi-
gation applies to NEC only [3, 23–28]. Our data indicate
that (i) the reported incremental trend observed for low-
grade NENs is conﬁrmed as a worldwide phenomenon, (ii)
that this trend occurs at most anatomical sites and (iii) it is
















































































































































































































































































































































































































































































































































The worldwide incremental trend for NENs is here
conﬁrmed at most anatomical sites investigated. No expla-
nation for this phenomenon is apparent. A mix of better
understanding of biology and clinical features of NEN and
better diagnosis was offered as the most likely interpretation
[17]. Though this could be the case, the link to potential
NEN-speciﬁc promoting agents cannot be excluded. As an
example and in line with this hypothesis the widespread
access to proton-pump inhibitors has been proposed as
possible risk factor for gastric NEN development [29].
Recent data from Norway however suggest a true increase
of NENs [18, 19].
The observed rapid increases in incidence rates asso-
ciated with signiﬁcant variations in national NEN incidence
rates. Our data indicate that geographic variations remained
stable over time, the highest incidence rates observed in
North America and relatively low rates in Taiwan. These
variations may well reﬂect heterogeneity in disease
classiﬁcation since classiﬁcation changes occurred in recent
years [2]. Nonetheless little is known of environmental,
ethnic/genetic or other risk/predisposing factors that could
be involved [30].
Here we report also the age-adjusted incidence rates of
NENs according to histological grade in US. Our data show
that the incidence of high-grade NENs is overall sig-
niﬁcantly higher when compared to low-grade NENs (10.52
vs. 3.51 per 100,000 in 2012). However, this reﬂects the
very high incidence observed for lung, as compared to
digestive NENs (7.47 vs. 1.72 per 100,000 in 2012). These
site-dependent features further conﬁrm signiﬁcant site-
speciﬁc differences.
In the period 2000–2012, the incidence rates of high-
grade NENs in SEER increased over time for all sites,
except for lung, where a decreasing trend was observed.
This latter observation may well reﬂect the change in
smoking habits in US over the last decades [31]. An
Fig. 3 a International incidence of NENs overall per 100,000 persons;
b Incidence of high-grade lung NEN, and low-grade and high-grade
NENs per 100,000 persons in the United States, 1973–2012;
c Incidence of low-grade NENs per 100,000 persons by primary site, in
the United States, 1973–2012; d Incidence of high-grade NENs per
100,000 persons by primary site, in the United States, 1973–2012
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increase in the incidence rate of low-grade NENs was also
observed at various anatomical sites (lung, rectum, stomach,
and appendix), whereas for others it remained stable (pan-
creas and small intestine) or decreased (colon). However,
when comparing the trends overall, the incidence increase
observed for high-grade NENs was only slightly higher, and
substantially in the same order of magnitude to that
observed for low-grade (high-grade 4.1-fold increase vs
low-grade 3.2).
Our data are the ﬁrst to report an incremental incidence
trend for digestive high-grade NENs. Very few epidemio-
logical data are available for this highly aggressive neu-
roendocrine cancer group, often excluded from
epidemiology investigation on NENs [7, 32]. This incre-
mental trend was consistently observed at all digestive sites
investigated, grossly paralleling that observed for low-grade
NENs.
Our ﬁndings raise the hypothesis that NENs share sus-
ceptibility factors independently of cancer grade, a phe-
nomenon observed for other cancer types. As an example,
in the upper and lower airways, smoking habits associate
with various carcinomas, no matter the histological type and
the cancer grade [33, 34]. High-grade cancer associates with
severe genetic somatic abnormalities, usually involving
genes controlling key cell proliferation pathways, and this is
true for NENs too [35]. As for NENs, it could be hypo-
thesized that the same, yet unknown factor(s) promote
neuroendocrine carcinogenesis, and may then result in
grade differences depending on the adding-on of key
genetic or epigenetic alterations (either synchronous or
metachronous).
As for gender and ethnicity, the general picture emerging
from our data is that the patient with low-grade NENs is
more frequently African–American of either sex, though
Table 3 NEN incidence per 100,000 by country and tumor site
NEN incidence per 100,000 All sites average increase
(cases per 100,000 per year)
Country Year Lung Stomach Pancreas Small intestine Colon Appendix Rectum All sites
North America
USA 1973 0.31 0.03 0.16 0.21 0.08 0.07 0.12 1.52 0.16
2012 1.61 0.45 0.82 1.28 0.30 0.22 1.10 7.41
Canada 1994 0.83 0.07 0.10 0.42 na na 0.22 2.46 0.23
2009 1.28 0.29 0.60 1.01 na na 0.96 5.86
Europe
The Netherlands 1990–00 0.68 0.15 0.19 0.32 0.13 0.58 0.19 3.57 0.11
2001–10 1.21 0.19 0.32 0.47 0.19 0.59 0.29 4.76
Germany 1976–78 na 0.01 0.06 0.13 0.05 0.28 0.01 na nc
2004–06 na 0.25 0.25 0.52 0.24 0.35 0.25 na
Italy 1985 na na na na na 0.00 na 0.50 0.07
2005 na na na na na 0.30 na 1.90
England 1971–78 na 0.01 na 0.12 0.18 0.04 0.01 na nc
2000–06 na 0.16 na 0.39 0.17 0.50 0.11 na
Sweden 1960–75 na na na 0.58 na na na na nc
1991–05 na na na 1.33 na na na na
Norway 1993–97 0.49 0.15 0.15 0.60 0.19 0.10 0.22 2.35 0.24
2000–04 0.90 0.20 0.30 1.01 0.33 0.23 0.25 4.06
France 1976 na na na 0.07 na na na na nc
2001 na na na 0.21 na na na na
Denmark 1978 0.20 na na na na na na na nc
1997 0.49 na na na na na na na
Switzerland 1974–85 0.33 0.01 na 0.16 na na na 0.77 0.05
1986–97 0.47 0.05 na 0.44 na na na 1.39
Asia
Taiwan 1996 0.05 0.02 0.02 0.03 0.02 na 0.07 0.30 0.11
2008 0.27 0.13 0.13 0.06 0.09 na 0.38 1.51
na not available, nc not computable
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prevalently female in case of NEN from the lung or the
stomach. Similarly, high-grade NENs were more frequently
observed in male African Americans, with the notable
exception of the lung (and at lesser extent the appendix)
for which NENs were predominantly observed in male
white patients. So, male gender and African American
ethnicity appear to play a role in determining NEN devel-
opment risk.
Finally, the incidence of NEN in the 2012 in 18 SEER
registries was 14.02 per 100,000, low-grade NEN being
approximately 25% of all, and up to 57% when the high-
grade NEN of the lung were excluded. In US, a cancer is
rare for an incidence lower than 15 in 100,000 people; while
in EU, a cancer is rare when lower than six in 100,000
people [36–38]. Our data suggest that NEN are close to
outgrow the current US categorization, and well above the
EU deﬁnition. In reality, when the high-grade NENs of the
lung are excluded, NEN incidence is considerably lower
(6.55 per 100,000) and far below the US cut-off deﬁnition
for rare cancer, but still higher than the EU deﬁnition. A
homogenous worldwide deﬁnition of rare cancer is prob-
ably needed, at least to uniform data analysis and to pro-
mote common cancer-speciﬁc policies.
Though we aimed at being as accurate as possible, some
methodological limits are present. In speciﬁc, different
morphological codes were used to classify NENs, and
different standard populations were used to adjust for dif-
ferences between countries in the age structure of the var-
ious populations. So, comparisons among different
geographical areas or populations were subject to some
bias. In addition, SEER data refer to tumors of proven
malignancy only, and since “carcinoids” for long have been
considered benign, this may have hampered data collection,
especially between 1973–2000. Despite such limits, this
study is based on data from 11 countries with a total
population of over 100 million. Also, SEER was used as
referral database since containing information on over 7.5
million cancer cases, providing the large number of events
required for reliable estimation of incidence in rare cancers
as NENs.
In conclusion, our data indicate that NENs overall are
stably increasing independently of grade. This yet poorly
understood phenomenon would require a major investiga-
tion effort to answer the expected rising demand for cure of
the increased NEN cancer patients, as well as prevention of
this group of neoplasms.
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